Adverse experiences with an incidence rate of less than 1% in the 60 mg q4h dose group were: hepatitis; itching; gastrointestinal hemorrhage; thrombocytopenia; anemia; palpitations; vomiting; flushing; diaphoresis; wheezing; phenytoin toxicity; lightheadedness; dizziness; rebound vasospasm; jaundice; hypertension; hematoma.Adverse experiences with an incidence rate less than 1% in the 90 mg q4h dose group were: itching, gastrointestinal hemorrhage; thrombocytopenia; neurological deterioration; vomiting; diaphoresis; congestive heart failure; hyponatremia; decreasing platelet count; disseminated intravascular coagulation; deep vein thrombosis.As can be seen from the table, side effects that appear related to nimodipine use based on increased incidence with higher dose or a higher rate compared to placebo control, included decreased blood pressure, edema and headaches which are known pharmacologic actions of calcium channel blockers.

The soft gelatin capsule shell contains gelatin, glycerin, purified water and titanium dioxide.Nimodipine is a calcium channel blocker.

It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop.In Europe, Nimotop was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension; this phenomenon was not observed in North American clinical trials.Nimodipine is metabolized via the cytochrome P450 3A4 system located both in the intestinal mucosa and in the liver. If there is a marked fall in blood pressure, dopamine or noradrenaline can be administered intravenously. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. No reproductive toxicology studies following parenteral administration are available. The distribution volume (Vss, 2 compartment model) for i.v. The frequencies of ADRs reported with nimodipine summarized in the tables below are based on clinical trials with nimodipine in the indication aSAH sorted by CIOMS III categories of frequency (placebo-controlled studies: nimodipine N = 703; placebo N = 692; uncontrolled studies: nimodipine N = 2496; status: 31 Aug 2005). In rabbits, equivocal evidence of teratogenicity was seen in one study at doses up to 10 mg/kg/day. Reproductive toxicology studies in animals after oral administration showed no teratogenic effect, although studies in animals have shown reproductive toxicity (see section 5.3). Gastric lavage with addition of charcoal should be considered as an emergency therapeutic measure. Nimodipine is isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate. and nimodipine bolus i.v. In a two-year study, higher incidences of adenocarcinoma of the uterus and Leydig-cell adenoma of the testes were observed in rats given a diet containing 1800 ppm nimodipine (equivalent to 91 to 121 mg/kg/day nimodipine) than in placebo controls. In each, a judgment was made as to whether any late-developing deficit was due to spasm or other causes, and the deficits were graded. Nimodipine is over 95% bound to plasma proteins.

By continuing to browse the site you are agreeing to our policy on the use of cookies. ]Capsules should be protected from light and freezing.©2007 Bayer HealthCare Pharmaceuticals Inc.13771Printed in USAThe easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. This medicinal product contains 1 mmol (23 mg) sodium per 50 ml bottle or 5.1 mmol (115 mg) sodium per 250 ml bottle, equivalent to 1.15 % or 5.75 %, respectively, of the WHO recommended maximum daily intake of 2 g sodium for an adult. Therefore, macrolide antibiotics should not be used in combination with nimodipine (see Azithromycin, although structurally related to the class of macrolide antibiotic is void of CYP3A4 inhibition.No formal studies have been performed to investigate the potential interaction between nimodipine and anti-HIV protease inhibitors. The intravenous Nimotop solution is 100% available to the tissues as the peripheral venous blood takes the drug to the lungs and heart and from there to all organs.